- $948.24m
- $487.03m
Brief: Jade Biosciences Files For Offering Of 3.2 Million Shares Of Common Stock By Selling Stockholder- SEC Filing
Brief: Jade Biosciences Announces $45 Million Private Placement
Brief: Jade Biosciences Files For Offering Of Up To 16.1 Million Shares Of Common Stock By The Selling Stockholders - SEC Filing
Brief: Jade Biosciences Announces First Cohort Dosed In Phase 1 Healthy Volunteer Clinical Trial Of Jade101, A Novel And Potentially Best-In-Class Anti-April Monoclonal Antibody Being Evaluated For The Treatment Of Iga Nephropathy
Jade Biosciences Inc expected to post a loss of 43 cents a share - Earnings Preview
Brief: Jade Biosciences Appoints Brad Dahms As Chief Financial Officer
Brief: Aerovate Therapeutics Stockholders Approve Proposed Merger With Jade Biosciences And All Related Proposals
Brief: Aerovate Therapeutics Declares Special Cash Dividend In Connection With The Proposed Merger With Jade Biosciences
Brief: Aerovate Therapeutics Announces Range Of Expected Cash Dividend
Aerovate Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Aerovate Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Aerovate Therapeutics - Exchange Ratio Assumes Valuation For Aerovate Of $8.0 Million And Valuation For Jade Of $175.0 Million
Brief: Aerovate Therapeutics And Jade Biosciences Announce Merger Agreement
Aerovate Therapeutics Inc expected to post a loss of 82 cents a share - Earnings Preview
Brief: Aerovate Therapeutics To Explore Strategic Alternatives
Brief: Aerovate Therapeutics On June 25, Determined To Implement A Reduction Of Company's Workforce
U.S. RESEARCH ROUNDUP-Aerovate Therapeutics, Boeing, Wingstop
U.S. RESEARCH ROUNDUP-Aerovate Therapeutics, Boeing, Wingstop
U.S. STOCKS ON THE MOVE-Broadcom, Xponential Fitness, Northfield Bancorp